Who May Be at Risk for Progressive Multifocal Leukoencephalopathy with Tysabri?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specialized Risk Communication

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection is linked to the JC virus and certain risk factors like longer treatment duration and prior immunosuppressant use. Building on established medical knowledge about drug safety monitoring, this page provides a neutral overview of who may be at higher risk and what current evidence says about risk stratification.

Bridging General Knowledge to Tysabri-Associated PML

The bridge concept reframes the legacy of general health information into a practical framework for managing risks in environments where biologic agents are routinely encountered. Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri highlighting this risk, and the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Clinical Presentation of PML

Three established risk factors increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected therapeutic benefit when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive decline, visual disturbances, or coordination problems. Diagnosis typically involves brain MRI and detection of JCV DNA in cerebrospinal fluid. Because PML can mimic multiple sclerosis relapses, an MRI scan should be obtained prior to initiating Tysabri in multiple sclerosis patients to help differentiate subsequent symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease patients, a baseline brain MRI may also be useful, though pre-existing lesions that could cause diagnostic difficulty are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Prognosis and Treatment for Severe PML After Tysabri

Prognosis for patients who develop PML after Tysabri exposure is generally poor. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment for severe PML after Tysabri primarily involves supportive care and restoration of immune function, often through plasma exchange or immunoadsorption to accelerate clearance of natalizumab from the circulation. However, immune reconstitution inflammatory syndrome (IRIS) can complicate recovery, as rapid immune recovery may trigger an exaggerated inflammatory response against JCV-infected cells, potentially worsening neurological injury. There are no approved antiviral therapies specifically for JCV infection, so management focuses on controlling IRIS with corticosteroids and providing symptomatic support. Outcomes vary, but many patients experience permanent neurological deficits, and mortality remains substantial. The timeline between Tysabri exposure and documented harm is influenced by treatment duration. Risk increases with longer therapy, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, monitoring for new signs or symptoms should continue for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed presentation underscores the need for prolonged vigilance even after therapy ends.

Adequacy of Warnings and Risk Mitigation

Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which clearly states the increased risk, identifies known risk factors, and mandates immediate withholding of dosing at first suspicion of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure prescribers and patients are informed of the risks and agree to monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML remains a serious and often devastating adverse effect, and the prognosis for affected patients is guarded. In summary, Tysabri-associated PML carries a high risk of death or severe disability. Treatment involves supportive care and immune reconstitution, but outcomes are frequently poor. Risk stratification based on anti-JCV antibody status, treatment duration, and prior immunosuppressant use is essential. Monitoring during therapy and for at least six months after discontinuation is critical for early detection. The existing warnings and restricted distribution program aim to mitigate risk, but the prognosis for patients who develop PML remains grave.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for patients who develop PML after Tysabri treatment?

The prognosis is generally poor. The boxed warning states that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Many patients experience permanent neurological deficits, and mortality remains substantial.

How is severe PML after Tysabri treated?

Treatment primarily involves supportive care and restoration of immune function, often through plasma exchange or immunoadsorption to accelerate clearance of natalizumab. Immune reconstitution inflammatory syndrome (IRIS) may complicate recovery and is managed with corticosteroids. There are no approved antiviral therapies specifically for JCV infection.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.